natgillin/translations-raw huggingface dataset:
A yellow, round, biconvex tablet, with 11 mm of diameter.
Žuta, okrugla, bikonveksna tableta, promjera 11 mm.
A yellow, round, biconvex tablet, with 12 mm of diameter.
Žuta, okrugla, bikonveksna tableta, promjera 12 mm.
A yellow, round, biconvex tablet, with 8 mm of diameter.
Žuta, okrugla, bikonveksna tableta, promjera 8 mm.
a – Logistic regression model adjusted for randomisation stratification variables
a – Model logističke regresije prilagođen za varijable randomizirane u stratuse
a – Progression-free survival (investigator assessed) b – Overall Response Rate = Complete Response + Partial Response c – Duration of response d - At the time of the reporting the majority (≥59%) of investigator-assessed responses were still ongoing e – ORR difference calculated based on the ORR result not rounded
a – Preživljenje bez progresije (procjena ispitivača) b – Ukupna stopa odgovora = kompletan odgovor + djelomični odgovor c – Trajanje odgovora d – U vrijeme izvješćivanja većina (≥ 59%) odgovora koje je procijenio ispitivač bila je još u tijeku e – Razlika u ORR-u izračunata na temelju rezultata za ORR koji nije bio zaokružen
A ‘booster’ injection should be given every year to maintain the vaccine’s effect.
Kako bi se održalo djelovanje cjepiva, svake godine treba primijeniti jednu „booster” injekciju.
a ‘Case’ = HIV seroconverter; ‘Cohort’ = 100 randomly selected subjects from each of the tenofovir disoproxil 245 mg (as fumarate) and Truvada groups.
a ‘Slučaj’ = osoba sa serokonverzijom HIV-a; ‘Kohorta = 100 nasumično odabranih ispitanika iz skupine koja je primala tenofovirdizoproksil u dozi od 245 mg (u obliku tenofovirdizoproksilfumarata) i skupine koja je primala Truvadu.
A ‘penile modeling procedure’ is then performed by the doctor after a further 1 to 3 days to gently stretch and bend the plaque in the opposite direction to the abnormal curvature.
Zatim liječnik provodi "postupak modeliranja penisa" nakon daljnja 1 do 3 dana pažljivog istezanja i savijanja plaka u suprotnom smjeru od normalne zakrivljenosti.
A ‘response’ was defined as a combination of a 10% improvement in exercise capacity (measured by looking at how far the patient could walk in six minutes) and an improvement of the patient’s condition (the severity of the disease going down by at least one class), without a worsening of pulmonary hypertension or death.
„Odgovor” se definira kao kombinacija poboljšanja od 10 % u kapacitetu tjelesne aktivnosti (mjeri se tako da se promatra koliko bolesnik može prehodati u 6 minuta) i poboljšanje bolesnikova stanja (težina bolesti mora se smanjiti barem za jednu klasu), bez pogoršanja plućne hipertenzije ili smrti.
A ‘response’ was defined as a fall in the levels of HIV in the blood (viral load) by 90% or more that was maintained until the end of the 48 weeks.
„Odgovor” je definiran kao snižavanje razina HIV-a u krvi (virusnu opterećenje) za 90% ili više, a koje je održano sve do kraja 48. tjedna.
A “Frequently asked questions” section
Odjeljak s "Često postavljanim pitanjima"
A “symptom responder” was defined as meeting both the 12-week responder criteria and demonstrating improvement in pre-specified OIC symptoms and no deterioration in symptoms.
"Bolesnik s odgovorom i poboljšanjem simptoma" definira se kao bolesnik koji je zadovoljio i kriterije odgovora na liječenje nakon 12 tjedana i ostvario poboljšanje unaprijed utvrđenih simptoma konstipacije uzrokovane primjenom opioida te nije imao pogoršanja simptoma.
A ≥ 2 step improvement in DRSS was assessed in a pre-specified manner in VIVIDDME and VISTADME.
U ispitivanjima VIVID-DME i VISTA-DME, procijenjeno je poboljšanje od ≥ 2 koraka u DRSS-u na unaprijed definirani način.
A&G Med Trading SRL Tel: +4021 332 49 91
A&G Med Trading SRL Tel: + 4021 332 49 91
a) % decrease of the mean trough level values b) Indinavir was only studied after a single dose of 400 mg isavuconazole.
a) % smanjenja srednjih vrijednosti najniţe razine lijeka b) Indinavir je ispitivan samo nakon jedne doze izavukonazola od 400 mg.
a) ADR explained in the section below.
a) Nuspojava objašnjena u dijelu u nastavku.
A) BCVA: Best Corrected Visual Acuity
A) BCVA: Najbolje korigirana oštrina vida
a) By bolus infusions
a) Infuzijama u obliku bolusa
A) Difference is Eylea 2 mg Q4 weeks minus control
A) Razlika je Eylea 2 mg svaka 4 tjedna minus kontrola
A) Difference is Eylea 2 mg Q4 weeks minus Laser Control
A) Razlika je Eylea 2 mg svaka 4 tjedna minus laserska kontrola
A) LOCF: Last Observation Carried Forward
A) LOCF (=Last Observation Carried Forward): zadnje mjerenje preneseno dalje
a) Rivaroxaban 20 mg once daily
a) Rivaroksaban 20 mg jedanput na dan
a) safety population, on treatment b) vs. placebo; Log-Rank p-value statistically significant
populacija za procjenu sigurnosti, na terapiji naspram placeba; Log-rank p-vrijednost statistički značajno
a* of 427 patients reporting prior TKI therapy with dasatinib or nilotinib b Of the patients with one or more BCR-ABL kinase domain mutations detected at entry, 37 unique mutations were detected.
a* od 427 bolesnika koji su prijavili prethodnu TKI terapiju dasatinibom ili nilotinibom b Među bolesnicima u kojih je pri uključivanju u ispitivanje uočena jedna ili više mutacija u domeni BCR-ABL kinaze, uočeno je 37 jedinstvenih mutacija.
A, B, D may interfere with some serological tests for red cell antibodies for example the direct antiglobulin test (DAT, direct Coombs’ test).
A, B, D, mogu interferirati s nekim serološkim testovima na protutijela na crvene krvne stanice, primjerice s izravnim antiglobulinskim testom (DAT, izravni Coombsov test).
A, B, D may interfere with some serological tests for red cell antibodies, for example the direct antiglobulin test (DAT, direct Coombs’ test).
A, B, D, mogu interferirati s nekim serološkim testovima na antitijela na crvene krvne stanice, primjerice s direktnim antiglobulinskim testom (DAT, izravni Coombsov test).
A, B, D, may interfere with some serological tests for red cell antibodies, for example the direct antiglobulin test (DAT, direct Coombs’ test).
A, B i D mogu interferirati s nekim serološkim testovima za protutijela eritrocita, primjerice s direktnim antiglobulinskim testom (DAT, direktni Coombsov test).
A, B, D, may interfere with some serological tests for red cell antibodies, for example the direct antiglobulin test (DAT, direct Coombs’ test).
A, B, D, može interferirati s nekim serološkim ispitivanjima za antitijela crvenih krvnih stanica, primjerice direktni antiglobulinski test (DAT, direktni Coombsov test).
A, B, D, may interfere with some serological tests for red cell antibodies, for example the direct antiglobulin test (DAT, direct Coomb’s test).
A, B, D, mogu interferirati s nekim serološkim testovima na protutijela na crvene krvne stanice, primjerice s izravnim antiglobulinskim testom (DAT, izravni Coombsov test).
A- 4020 Linz, Austria
A-4020 Linz, Austrija
a- Summary of the safety profile
a- Sažetak sigurnosnog profila
A-1121 Vienna Austria
A-1121 Beč
A-1221 Vienna Austria
Austrija
A-1221 Vienna Austria
Industriestrasse 67 A-1221 Beč
A-1221 Vienna, Austria
A-1221 Beč, Austrija
A-2491 Neufeld/Leitha Austria
A-2491 Neufeld/Leitha Austrija
A-4020 Linz Austria
A-4020 Linz Austrija
A-4020 Linz Austria
A-4020 Linz Austrija‌‌
A-4866 Unterach Austria
4866 Unterach Austrija
A-6250 Kundl Austria
A-6250 Kundl Austrija
A.
O.
A. Ask your doctor, nurse, or pharmacist about national and local laws regarding the proper disposal of medical products that contain needles.
Pitajte svog liječnika, medicinsku sestru ili ljekarnika o nacionalnim i lokalnim propisima koji se odnose na pravilno odlaganje medicinskih proizvoda koji sadrže igle.
A. Before lifting the Pen from the injection site, check to ensure that the blue indicator has stopped moving.
Prije nego što podignete brizgalicu s mjesta injekcije, provjerite da li se plavi indikator prestao pomicati.
A. Before the injection can be triggered, the device must be unlocked.
Da bi injiciranje moglo započeti, brizgalica se prvo mora otključati.
A. Contact your healthcare provider.
O. Obratite se svom zdravstvenom radniku.
A. Do not use the Pen.
Nemojte upotrijebiti brizgalicu.
A. Generally, this is allowed.
U načelu je to dopušteno.
A. If you remove the cover before you are ready to use the Pen, be careful.
Ako skinete pokrov prije nego što ste spremni upotrijebiti brizgalicu, budite oprezni.
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. PROIZVOĐAČ BIOLOŠKE DJELATNE TVARI I PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. PROIZVOĐAČ BIOLOŠKI DJELATNE TVARI I PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE U PROMET
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
A. PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
UVJETI ILI OGRANIČENJA VEZANI UZ OPSKRBU I PRIMJENU
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE‌‌
A. PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET‌‌
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE‌‌‌
A. PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET‌‌‌
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
A. PROIZVOĐAČ(I) ODGOVORAN(ODGOVORNI) ZA PUŠTANJE SERIJE LIJEKA U PROMET
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE‌
PROIZVOĐAČ(I) ODGOVORAN(ODGOVORNI) ZA PUŠTANJE SERIJE LIJEKA U PROMET‌‌
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE‌‌
A. PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET‌‌
A. Menarini Pharmaceuticals Ltd Tel: +353 1 284 6744
Berlin-Chemie A. Menarini S.R.L Tel: +40 211 232 34 32
A. Potamitis Medicare Ltd Τηλ: +357 22583333
A. Potamitis Medicare Ltd
A. This step is primarily for your comfort.
Ovaj se korak provodi prvenstveno radi Vaše ugode.
A. When giving an injection, you may feel a prick from the needle.
Kada primjenjujete injekciju, možete osjetiti ubod igle.
A. Your doctor, nurse, or pharmacist may be familiar with special carrying cases for injectable medicines.
Vaš liječnik, medicinska sestra ili ljekarnik mogli bi biti upoznati s posebnim spremnicima za prenošenje lijekova za injiciranje.
A.Potamitis Medicare Ltd Τηλ: +357 22583333 a.potamitismedicare@cytanet.com.cy
A. Potamitis Medicare Ltd Τηλ: +357 22583333 a.potamitismedicare@cytanet.com.cy
A/California/07/2009 (H1N1) derived strain used NYMC X-179A 3.75 micrograms**
A/California/07/2009 (H1N1) iz kojeg je izveden korišteni soj NYMC X-179A 3,75 mikrograma
A/California/07/2009 (H1N1) derived strain used NYMC X-179A 3.75 micrograms** per 0.5 ml dose
A/California/07/2009 (H1N1) iz kojeg je izveden korišteni soj NYMC X-179A 3,75 mikrograma** po dozi od 0,5 ml
A/California/07/2009 (H1N1)-derived strain used NYMC X-181 7.5 micrograms ** per 0.5 ml dose
A/California/07/2009 (H1N1)-iz kojeg je izveden korišten soj NYMC X-181 7,5 mikrograma** po dozi od 0,5 ml
A/California/07/2009 (H1N1)-derived strain used NYMC X-181 7.5 micrograms haemagglutinin
A/California/07/2009 (H1N1)- iz kojeg je izveden korišten soj NYMC X-181 7,5 mikrograma hemaglutinina
A/California/07/2009 (H1N1)-derived strain used NYMC X-181 7.5 micrograms** per 0.5 ml dose
A/California/07/2009 (H1N1) -iz kojeg je izveden korišten soj NYMC X-181 7,5 mikrograma** po dozi od 0,5 ml
A/California/07/2009 (H1N1)-derived strain used NYMC X-181 7.5 micrograms** per 0.5 ml dose
A/California/07/2009 (H1N1)- iz kojeg je izveden korišten soj NYMC X-181 7,5 mikrograma** po dozi od 0,5 ml
A/California/07/2009 (H1N1)v 7.5 microgram** per 0.5 ml dose
A/California/07/2009 (H1N1)v 7,5 mikrograma** po dozi od 0,5 ml
A/California/07/2009 (H1N1)v 7.5 micrograms** per 0.5 ml dose
A/California/07/2009 (H1N1)v 7,5 mikrograma** po dozi od 0,5 ml
A/California/7/2009 (H1N1)pdm09 - like strain (A/Bolivia/559/2013, MEDI 255962) 107.0±0.5 FFU***
A/California/7/2009 (H1N1)pdm09 - poput kojeg je korišten soj (A/Bolivia/559/2013, MEDI 255962) 107,0±0,5 FFU
A/California/7/2009 (H1N1)pdm09 - like strain (A/Brisbane/10/2010, wild type) 15 micrograms HA**
soj sličan A/California/7/2009 (H1N1)pdm09 (divlji tip A/Brisbane/10/2010) 15 mikrograma HA
A/California/7/2009 (H1N1)pdm09 - like strain (A/California/7/2009, NYMC X-179A)
A/California/7/2009 (H1N1)pdm09 - sličan soj (A/California/7/2009, NYMC X-179A)
A/California/7/2009 (H1N1)pdm09 - like strain (A/California/7/2009, NYMC X-179A)..........
A/California/7/2009 (H1N1)pdm09 - sličan soj (A/California/7/2009, NYMC X-179A)..................................15 mikrograma HA
A/California/7/2009 (H1N1)pdm09 - like strain A/Hong Kong/4801/2014 (H3N2) - like strain B/Brisbane/60/2008 - like strain
A/Hong Kong/4801/2014 (H3N2) - sličan soj B/Brisbane/60/2008 - sličan soj
A/California/7/2009 (H1N1)pdm09-like strain (A/Bolivia/559/2013, MEDI 255962) A/Hong Kong/4801/2014 (H3N2) - like strain (A/New Caledonia/71/2014, MEDI 263122) B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, MEDI 228030) B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, MEDI 254977)
A/California/7/2009 (H1N1)pdm09 - poput kojeg je korišten soj (A/Bolivia/559/2013, MEDI 255962) A/Hong Kong/4801/2014 (H3N2) - poput kojeg je korišten soj (A/New Caledonia/71/2014, MEDI 263122) B/Brisbane/60/2008 - poput kojeg je korišten soj (B/Brisbane/60/2008, MEDI 228030) B/Phuket/3073/2013 - poput kojeg je korišten soj (B/Phuket/3073/2013, MEDI 254977)
A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029) 107.0±0.5 FFU***
A/California/7/2009 (H1N1) pdm09 kao soj (A/California/7/2009, MEDI 228029) 107,0±0,5 FFU
A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029) 107.0±0.5 FFU***
A/California/7/2009 (H1N1)pdm09 kao soj (A/California/7/2009, MEDI 228029) 107,0±0,5 FFU
A/California/7/2009 (H1N1)pdm09-like strain (A/California/7/2009, MEDI 228029) 107.0±0.5 FFU*** A/Victoria/361/2011 (H3N2)-like strain (A/Texas/50/2012, MEDI 237514) 107.0±0.5 FFU*** B/Massachusetts/2/2012-like strain (B/Massachusetts/2/2012, MEDI 237751) 107.0±0.5 FFU***
A/California/7/2009 (H1N1)pdm09 kao soj (A/California/7/2009, MEDI 228029) 107,0±0,5 FFU*** A/Victoria/361/2011 (H3N2) kao soj (A/Texas/50/2012, MEDI 237514) 107,0±0,5 FFU*** B/Massachusetts/2/2012 kao soj (B/Massachusetts/2/2012, MEDI 237751) 107,0±0,5 FFU
A/equine-2/ South Africa/4/03 50 AU1
A/equine-2/Južna Afrika/4/03 50 AU1
A/H5N1/Indonesia/5/2005 like strain used (PR8-IBCDC-RG2)3.75 micrograms** per 0.5 ml dose
A/Indonesia/05/2005 (H5N1) poput kojeg je korišten soj (PR8-IBCDC-RG2)3,75 mikrograma** po dozi od 0,5 ml
A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B)
A/Hong Kong/4801/2014 (H3N2) - sličan soj (A/Hong Kong/4801/2014, NYMC X-263B)
A/Hong Kong/4801/2014 (H3N2) - like strain (A/New Caledonia/71/2014, MEDI 263122) 107.0±0.5 FFU***
A/Hong Kong/4801/2014 (H3N2) - poput kojeg je korišten soj (A/New Caledonia/71/2014, MEDI 263122) 107,0±0,5 FFU
A/Hong Kong/4801/2014 (H3N2) - like strain B/Brisbane/60/2008 - like strain
A/Hong Kong/4801/2014 (H3N2) - sličan soj B/Brisbane/60/2008 - sličan soj
A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2) 3.75 micrograms* AS03 adjuvant composed of squalene, DL--tocopherol and polysorbate 80
A/Indonesia/05/2005 (H5N1) poput kojeg je korišten soj (PR8-IBCDC-RG2) 3,75 mikrograma* AS03 adjuvans sadrži skvalen, DL--tokoferol i polisorbat 80
A/Indonesia/5/2005 (H5N1) like strain used (PR8-IBCDC-RG2) I.M.
A/Indonesia/05/2005 (H5N1) poput kojeg je korišten soj (PR8-IBCDC-RG2) i.m.
A/New Caledonia/ 20/99
A/New Caledonia/20/99
A/turkey/Turkey/1/05 (H5N1)-like strain (NIBRG-23) 7.5 micrograms haemagglutinin
A/turkey/Turkey/1/05 (H5N1) -poput kojeg je korišten soj (NIBRG-23) 7,5 mikrograma hemaglutinina
A/Victoria/361/2011 (H3N2)-like strain (A/Texas/50/2012, MEDI 237514) 107.0±0.5 FFU***
A/Victoria/361/2011 (H3N2) kao soj (A/Texas/50/2012, MEDI 237514) 107,0±0,5 FFU
A/Vietnam/1194/2004 (H5N1) 7.5 micrograms ** per 0.5 ml dose
A/Vietnam/1194/2004 (H5N1) 7,5 mikrograma** po dozi od 0,5 ml
A/Vietnam/1194/2004 (H5N1) 7.5 micrograms haemagglutinin
A/Vietnam/1194/2004 (H5N1) 7,5 mikrograma hemaglutinina
A/Vietnam/1194/2004 (H5N1) like strain used (NIBRG-14) 3.75 micrograms** per 0.5 ml dose
A/VietNam/1194/2004 (H5N1) poput kojeg je korišten soj (NIBRG-14) 3,75 mikrograma** po dozi od 0,5 ml
A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14) I.M.
A/VietNam/1194/2004 (H5N1) poput kojeg je korišten soj (NIBRG-14) i.m.
A/Vietnam/1194/2004 (H5N1)-like strain (NIBRG-14) 7.5 micrograms haemagglutinin
A/Vietnam/1194/2004 (H5N1)-poput kojeg je korišten soj (NIBRG-14) 7,5 mikrograma hemaglutinina
A/Vietnam/1203/2004 (H5N1) 7.5 microgram** per 0.5 ml dose
A/Vietnam/1203/2004 (H5N1) 7,5 mikrograma** po dozi od 0,5 ml
A/Vietnam/1203/2004 (H5N1) 7.5 micrograms** per 0.5 ml dose
A/Vietnam/1203/2004 (H5N1) 7,5 mikrograma** po dozi od 0,5 ml
A/Vietnam/1203/2004 (H5N1) strain (A/Vietnam/1203/2004, MEDI 0141000136) 107.0±0.5 FFU
A/Vietnam/1203/2004 (H5N1) soj (A/Vietnam/1203/2004, MEDI 0141000136) 107.0±0.5 FFU
A/Vietnam/1203/2004 (H5N1) strain (A/Vietnam/1203/2004, MEDI 0141000136) 107.0±0.5 FFU***
A/Vietnam/1203/2004 (H5N1) soj (A/Vietnam/1203/2004, MEDI 0141000136) 107.0±0,5 FFU
A/Vietnam/1203/2004 (H5N1) strain (A/Vietnam/1203/2004, MEDI 0141000136) 107.0±0.5 FFU***
A/Vietnam/1203/2004 (H5N1) soj (A/Vietnam/1203/2004, MEDI 0141000136) 107.0±0.5 FFU
A/Wisconsin/ 67/2005
A/Winconsin/67/2005
a1 morning, 2 evening b2 morning, 2 evening
a1 ujutro, 2 navečer b2 ujutro, 2 navečer
a1000 mg/m2 oral twice daily for 14 days administered every 3 weeks bStratified analysis included all progression and death events except those where non-protocol therapy (NPT) was initiated prior to documented progression; data from those patients were censored at the last tumour assessment prior to starting NPT.
a1000 mg/m2 peroralno dvaput na dan tijekom 14 dana, svaka 3 tjedna bStratificirana analiza obuhvatila je sve događaje progresije i smrti izuzev tamo gdje je prije nego je utvrđena progresija uvedena terapija koja nije obuhvaćena protokolom ispitivanja; podaci o ovim bolesnicima su izostavljeni kod posljednje procjene tumora prije uvođenja terapije koja nije obuhvaćena protokolom.
A22 Iraq and A24 Cruzeiro
A22 Iraq i Asia1 Shamir
A22 Iraq and Asia1 Shamir
A24 Cruzeiro i A Turkey 14/98
A22 Iraq, A24 Cruzeiro and Asia1 Shamir
AFTOVAXPUR DOE
A22 Iraq, Asai1 Shamir and SAT2 Saudi Arabia
A22 Iraq, Asia1 Shamir & SAT2 Saudi Arabia
A22 Iraq..................................................................................................................................... ≥ 6 PD50*
A22 Iraq......................................................................................................................................≥ 6 PD50
A230T
R227P
A24 Cruzeiro ............................................................................................................................. ≥ 6 PD50*
A24 Cruzeiro ..............................................................................................................................≥ 6 PD50
A24 Cruzeiro and A Turkey 14/98
A24 Cruzeiro i Asia 1 Shamir
A24 Cruzeiro and Asia 1 Shamir
A Turkey 14/98 i Asia 1 Shamir
A24 Cruzeiro and SAT2 Saudi Arabia
A Cruzeiro & SAT2 Saudi Arabia
A24 Cruzeiro, Asia 1 Shamir and SAT2 Saudi Arabia
A24 Cruzeiro, Asia1 Shamir & SAT2 Saudi Arabia
A368T
R363H
A5 species (HPV 51)
Vrsta A5 (HPV 51)
A6 species (HPV 56)
Vrsta A6 (HPV 56)
A73E
M76R
A73V
M72I
a: 1 morning, 2 evening b: 2 morning, 2 evening
a: 1 ujutro, 2 uvečer b: 2 ujutro, 2 uvečer
a: 2 morning, 2 evening
a: 2 ujutro, 2 navečer
a: 25 mg Enbrel SC twice weekly b: p < 0.001, Enbrel vs. placebo c: p < 0.01, Enbrel vs. placebo
a: 25 mg Enbrela supkutano, dva puta tjedno b: p < 0,001, Enbrel u odnosu na placebo c: p < 0,01, Enbrel u odnosu na placebo
A: Contact your doctor or nurse if you need a replacement part or if you need to replace your entire pen.
O: Obratite se svom liječniku ili medicinskoj sestri ako trebate zamjenski dio ili morate zamijeniti cijelu brizgalicu.
a: Further dose reductions should be considered on an individual patient basis as limited data are available for doses below 10 mg.
a: Daljnja sniženja doze treba razmotriti u svakog bolesnika pojedinačno jer su dostupni podaci za doze niže od 10 mg ograničeni.
a: Identified from the clinical trial b: Identified from Post Marketing experience c: Identified from Post-Marketing experience, experienced by healthcare personnel following accidental exposure d: Post Marketing Safety Surveillance (PMSS) data, effects associated with acute withdrawal of the medicinal product, and /or delivery system failures.
a: Podaci iz kliničkih ispitivanja b: Podaci iz iskustva nakon stavljanja lijeka u promet. c: Podaci iz iskustva nakon stavljanja lijeka u promet, iskustvo medicinskih djelatnika nakon slučajnog izlaganja d: Podaci iz ispitivanja sigurnostinakon stavljanja lijeka u promet (PMSS, engl.
a: Identified from the clinical trial b: Identified from Post-Marketing experience c: Identified from Post-Marketing experience, experienced by healthcare personnel following accidental exposure d: Post Marketing Safety Surveillance (PMSS) data, effects associated with acute withdrawal of the medicinal product, and /or delivery system failures.
a: Podaci iz kliničkih ispitivanja b: Podaci iz iskustva nakon stavljanja lijeka u promet. c: Podaci iz iskustva nakon stavljanja lijeka u promet, iskustvo medicinskih djelatnika nakon slučajnog izlaganja d: Podaci iz ispitivanja sigurnostinakon stavljanja lijeka u promet (PMSS, engl.
A: LABELLING
A: OZNAČAVANJE
a: Negative change in score indicates improvement. b: Only patients having both baseline and at least one post baseline were included.
a: Negativna promjena u rezultatu označava poboljšanje. b: Bili su uključeni samo bolesnici za koje se imala početna i još barem jedna vrijednost nakon početne.
A: observed in prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery
A: opažene kod prevencije venske tromboembolije (VTE) u odraslih bolesnika koji se podvrgavaju elektivnom kirurškom zahvatu ugradnje umjetnog kuka ili koljena.
A: observed in prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery
A: uočeno kod prevencije venske tromboembolije (VTE) u odraslih bolesnika koji se podvrgavaju elektivnom kirurškom zahvatu zamjene kuka ili koljena
a: one fatal case b: One pleural effusion fatal event occurred in the low-dose (175/25 mg) arm of the MCL study
a: svaki uključuje po jedan smrtni slučaj b: Jedan smrtonosni slučaj pleuralnog izljeva dogodio se u skupini koja je primala nisku dozu (175/25 mg) lijeka u ispitivanju MCL
a: p <0.001, Enbrel vs. placebo
a: p<0,001, Enbrel u odnosu na Placebo
a: p<0.001, Enbrel vs. placebo
a: p<0,001, Enbrel u odnosu na Placebo
a: Pearson’s chi-square test of difference between placebo and eptifibatide.
a Pearsonov hi-kvadrat test razlike između placeba i eptifibatida.
a: Pearson’s chi-square test of difference between placebo and eptifibatide.
a: Paersonov hi-kvadrat razlike između placeba i eptifibatida.
a: Response to treatment was defined as undetectable HCV-RNA at 24 weeks post-treatment, lower limit of detection = 125 IU/ml.
a: Odgovor na liječenje definiran je kao nemjerljiva razina HCV-RNK u 24. tjednu nakon liječenja, donja granica detekcije = 125 IU/ml
a: Response to treatment was defined as undetectable HCV-RNA at 24 weeks post-treatment, lower limit of detection=125 IU/mL.
a: Odgovor na liječenje definiran je kao nemjerljiva razina HCV-RNK u 24. tjednu nakon liječenja, donja granica detekcije = 125 IU/ml
A: The NutropinAq Pen is designed to last 24 months from the time you first use your pen.
O: NutropinAq brizgalica dizajnirana je kako bi trajala 24 mjeseca od prve uporabe.
a: TMZ dose levels are listed in Table 2. b: TMZ is to be discontinued if:
a: razine doza TMZ-a navedene su u Tablici 2. b: TMZ se mora prekinuti: